Nadolol (Nadolol)
Overview of Nadolol
Nadolol is oral, nonselective, beta-adrenergic receptor antagonist similar to propranolol. Chemically Nadolol is identified as (2R, 3S)-5-[ 3-(tert-butylamino)-2-hydroxypropoxy ]-1, 2, 3, 4-tetrahydronaphthalene-2, 3-diol. It does not demonstrate appreciable intrinsic sympathomimetic or membrane-stabilizing activities. Unlike propranolol, it possesses a low degree of lipid solubility and has the longest plasma half-life of all the beta-adrenergic-blocking agents. It was approved by the FDA in December 1989. The actions and uses similar to that of propranolol, but Nadolol is more potent than propranolol. It slows the heart rate and reduces high blood pressure
Indication of Nadolol
Nadolol is primarily indicated in conditions like Angina, Cardiac arrhythmia, Control of muscarinic side-effects of neostigmine, Hypertension, Hyperthyroidism, Migraine prophylaxis, Myocardial infarction, Thyrotoxicosis, To prevent recurrence of neural tube defect.
Contraindication of Nadolol
Nadolol is contraindicated in conditions like Cardiogenic shock,Heart block,Cardiac insufficiency,Obstructive airway disease.
Side Effects of Nadolol
Nadolol produces potentially life-threatening effects which include Bronchospasm, Heart block, Bronchospasm, Heart failure, Asthma. which are responsible for the discontinuation of Nadolol therapy.,The symptomatic adverse reactions produced by Nadolol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Alopecia, Insomnia, Confusion, Bradycardia, Dryness of mouth, Depression, Light headedness, Paresthesias, Cardiac insufficiency, Amnesia, Coolness of extremities, Confusion, Alopecia.
Precautions of Nadolol
Nadolol should be used with caution in diabetic patients and patients with kidney or liver disease.